<?xml version="1.0" ?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.3 20210610//EN"  "JATS-archivearticle1-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">elife</journal-id>
<journal-id journal-id-type="publisher-id">eLife</journal-id>
<journal-title-group>
<journal-title>eLife</journal-title>
</journal-title-group>
<issn publication-format="electronic" pub-type="epub">2050-084X</issn>
<publisher>
<publisher-name>eLife Sciences Publications, Ltd</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">89690</article-id>
<article-id pub-id-type="doi">10.7554/eLife.89690</article-id>
<article-id pub-id-type="doi" specific-use="version">10.7554/eLife.89690.1</article-id>
<article-version-alternatives>
<article-version article-version-type="publication-state">reviewed preprint</article-version>
<article-version article-version-type="preprint-version">1.1</article-version>
</article-version-alternatives>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Cell Biology</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Binding of LncRNA-DACH1 to dystrophin impairs the membrane trafficking of Nav1.5 protein and increases ventricular arrhythmia susceptibility</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1011-0954</contrib-id>
<name>
<surname>Pan</surname>
<given-names>Zhenwei</given-names>
</name>
<email>panzw@ems.hrbmu.edu.cn</email>
<xref ref-type="aff" rid="a1"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Xue</surname>
<given-names>Gen-Long</given-names>
</name>
<xref ref-type="aff" rid="a1"/>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6680-3098</contrib-id>
<name>
<surname>Zhang</surname>
<given-names>Yang</given-names>
</name>
<xref ref-type="aff" rid="a1"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Yang</surname>
<given-names>Jiming</given-names>
</name>
<xref ref-type="aff" rid="a1"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Yang</surname>
<given-names>Ying</given-names>
</name>
<xref ref-type="aff" rid="a1"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zhang</surname>
<given-names>Ruixin</given-names>
</name>
<xref ref-type="aff" rid="a1"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Li</surname>
<given-names>Desheng</given-names>
</name>
<xref ref-type="aff" rid="a1"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Tian</surname>
<given-names>Tao</given-names>
</name>
<xref ref-type="aff" rid="a1"/>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9866-2018</contrib-id>
<name>
<surname>Zhang</surname>
<given-names>Xiaofang</given-names>
</name>
<xref ref-type="aff" rid="a1"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Li</surname>
<given-names>Changzhu</given-names>
</name>
<xref ref-type="aff" rid="a1"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Li</surname>
<given-names>Xingda</given-names>
</name>
<xref ref-type="aff" rid="a1"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Yang</surname>
<given-names>Jiqin</given-names>
</name>
<xref ref-type="aff" rid="a1"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Shen</surname>
<given-names>Kewei</given-names>
</name>
<xref ref-type="aff" rid="a1"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Guo</surname>
<given-names>Yang</given-names>
</name>
<xref ref-type="aff" rid="a1"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Liu</surname>
<given-names>Xuening</given-names>
</name>
<xref ref-type="aff" rid="a1"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Yang</surname>
<given-names>Guohui</given-names>
</name>
<xref ref-type="aff" rid="a1"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lu</surname>
<given-names>Yanjie</given-names>
</name>
<xref ref-type="aff" rid="a1"/>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0125-1608</contrib-id>
<name>
<surname>Yang</surname>
<given-names>Baofeng</given-names>
</name>
<xref ref-type="aff" rid="a1"/>
</contrib>
<aff id="a1"><institution>Harbin Medical University</institution></aff>
</contrib-group>
<contrib-group content-type="section">
<contrib contrib-type="editor">
<name>
<surname>Colecraft</surname>
<given-names>Henry M</given-names>
</name>
<role>Reviewing Editor</role>
<aff>
<institution-wrap>
<institution>Columbia University</institution>
</institution-wrap>
<city>New York</city>
<country>United States of America</country>
</aff>
</contrib>
<contrib contrib-type="senior_editor">
<name>
<surname>Swartz</surname>
<given-names>Kenton J</given-names>
</name>
<role>Senior Editor</role>
<aff>
<institution-wrap>
<institution>National Institute of Neurological Disorders and Stroke</institution>
</institution-wrap>
<city>Bethesda</city>
<country>United States of America</country>
</aff>
</contrib>
</contrib-group>
<pub-date pub-type="epub">
<day>04</day>
<month>02</month>
<year>2021</year>
</pub-date>
<pub-date date-type="original-publication" iso-8601-date="2023-09-01">
<day>01</day>
<month>09</month>
<year>2023</year>
</pub-date>
<volume>12</volume>
<elocation-id>RP89690</elocation-id>
<history><date date-type="sent-for-review" iso-8601-date="2023-06-27">
<day>27</day>
<month>06</month>
<year>2023</year>
</date>
</history>
<pub-history>
<event>
<event-desc>Preprint posted</event-desc>
<date date-type="preprint" iso-8601-date="2021-02-04">
<day>04</day>
<month>02</month>
<year>2021</year>
</date>
<self-uri content-type="preprint" xlink:href="https://doi.org/10.21203/rs.3.rs-156367/v1"/>
</event>
</pub-history>
<permissions>
<copyright-statement>© 2023, Pan et al</copyright-statement>
<copyright-year>2023</copyright-year>
<copyright-holder>Pan et al</copyright-holder>
<ali:free_to_read/>
<license xlink:href="https://creativecommons.org/licenses/by/4.0/">
<ali:license_ref>https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
<license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="elife-preprint-89690-v1.pdf"/>
<abstract>
<title>Abstract</title>
<p>Dystrophin is a critical interacting protein of Nav1.5 that determines its membrane anchoring in cardiomyocytes. The study aims to explore whether lncRNA-DACH1(lncDACH1) can regulate the distribution of Nav1.5 by binding to dystrophin and participate in ventricular arrhythmogenesis. LncDACH1 was confirmed to bind to dystrophin. Cardiomyocyte-specific transgenic overexpression of lncDACH1(lncDACH1-TG) reduced the membrane distribution of dystrophin and Nav1.5 in cardiomyocytes. The opposite data were collected from lncDACH1 cardiomyocyte conditional knockout (lncDACH1-CKO) mice. Moreover, increased ventricular arrhythmia susceptibility was observed in lncDACH1-TG mice <italic>in vivo</italic> and <italic>ex vivo</italic>. The conservative fragment of lncDACH1 inhibited membrane distribution of dystrophin and Nav1.5 and promoted the inducibility of ventricular arrhythmia. Upregulation of dystrophin in lncDACH1-TG mice rescued the impaired membrane distribution of dystrophin and Nav1.5. The human homologue of lncDACH1 inhibited the membrane distribution of Nav1.5 in human iPS-differentiated cardiomyocytes. Collectively, lncDACH1 regulates Nav1.5 membrane distribution by binding to dystrophin and participates in ventricular arrhythmogenesis.</p>
</abstract>
<kwd-group>
<title>Keywords</title>
<kwd>LncDACH1</kwd>
<kwd>dystrophin</kwd>
<kwd>Nav1.5</kwd>
<kwd>ventricular arrhythmia</kwd>
</kwd-group>

</article-meta>
<notes>
<notes notes-type="competing-interest-statement">
<title>Competing interests</title>
<p>The authors declare no competing interests.</p>
</notes>
</notes>
</front>
<body>
<sec id="s1" sec-type="intro">
<title>Introduction</title>
<p>The voltage gated sodium channel mediates the 0 phase depolarizing inward sodium currents of cardiomyocytes<sup><xref ref-type="bibr" rid="c1">1</xref></sup>. The expression and function of sodium channel is regulated at multiple levels encompassing gene mutation, post-transcriptional modification, post-translational modification and protein trafficking etc<sup><xref ref-type="bibr" rid="c1">1</xref>, <xref ref-type="bibr" rid="c2">2</xref></sup>. The disruption of either process is arrhythmogenic and occasionally causes sudden death<sup><xref ref-type="bibr" rid="c2">2</xref>, <xref ref-type="bibr" rid="c3">3</xref></sup>.</p>
<p>The membrane targeting and localization of pore-forming subunit of sodium channel Nav1.5 was regulated by several interacting proteins such as ankyrin-G, MOG1, syntrophin and dystrophin etc<sup><xref ref-type="bibr" rid="c2">2</xref>, <xref ref-type="bibr" rid="c4">4</xref></sup>. Dystrophin is a cytoplasmic protein that is encoded by duchenne muscular dystrophy (DMD) gene<sup><xref ref-type="bibr" rid="c5">5</xref></sup>. It distributes mainly on the cellular membrane of skeletal muscle cells and cardiomyocytes, and acts as a scaffold for Nav1.5<sup><xref ref-type="bibr" rid="c6">6</xref></sup>. In cardiomyocytes, dystrophin controls the expression and membrane anchoring of Nav1.5. Gavillet et al. showed that knockout of dystrophin in cardiomyocytes reduced peak sodium current, Nav1.5 protein expression and conduction velocity in mice<sup><xref ref-type="bibr" rid="c6">6</xref></sup>. Subsequently, they confirmed that knockout of dystrophin inhibits membrane distribution of Nav1.5 due to the disruption of dystrophin-syntrophin complex<sup><xref ref-type="bibr" rid="c7">7</xref></sup>.</p>
<p>Long noncoding RNAs (LncRNAs) are a new class of RNAs that are more than 200 nts long and possess little protein coding property.<sup><xref ref-type="bibr" rid="c8">8</xref></sup> LncRNAs have been shown to regulate multiple biological processes and participate in the pathogenesis of various diseases including cardiac diseases<sup><xref ref-type="bibr" rid="c9">9</xref></sup>. LncRNAs were shown to regulate cardiac electrophysiological property by altering the function of different ion channels. For example, the increased expression of lncRNA-Kcna2as in heart failure reduced <italic>I</italic><sub>ks</sub> and prolonged action potential duration (APD)<sup><xref ref-type="bibr" rid="c10">10</xref></sup>. LncRNA-MALAT1 enhanced arrhythmia susceptibility by suppressing <italic>I</italic><sub>to</sub> and prolonging APD<sup><xref ref-type="bibr" rid="c11">11</xref></sup>. In a previous study, we found that lncRNA-CCRR (cardiac conduction regulatory) interacts with connexin-43 interacting protein 85(CIP85) to promote connexin-43 membrane distribution and improve the impaired cardiac conduction of failing hearts<sup><xref ref-type="bibr" rid="c12">12</xref></sup>. However, to date, it remains unknown whether and how lncRNA regulates sodium channel.</p>
<p>LncDACH1 is an intronic lncRNA located on the first intron of <italic>DACH1</italic> gene<sup><xref ref-type="bibr" rid="c13">13</xref></sup>. We previously showed that lncDACH1 impairs cardiac function by promoting the degradation of sarco-endoplasmic reticulum ATPase 2a (SERCA2a), and exacerbates cardiac ischemia injury by inhibiting Yes-associated protein 1(YAP1) mediated proliferation of neonatal cardiomyocytes<sup><xref ref-type="bibr" rid="c13">13</xref>, <xref ref-type="bibr" rid="c14">14</xref></sup>. During analyzing the interacting proteins of lncDACH1 identified by mass spectrometry, we found that dystrophin is one of them, which drove us to hypothesize that lncDACH1 may be a critical regulator of sodium channel Nav1.5.</p>
<p>Therefore, in this study we explored whether lncDACH1 regulates Nav1.5 by interacting with dystrophin. We found that lncDACH1 inhibited the membrane trafficking of Nav1.5 by binding to dystrophin, which led to reduced sodium current and increased ventricular arrhythmia susceptibility. The study highlights a novel mechanism for the regulation of sodium channel trafficking, and reveals a potential therapeutic target for sodium channel dysfunction related cardiac arrhythmias.</p>
</sec>
<sec id="s2" sec-type="results">
<title>Results</title>
<sec id="s2a">
<title>LncDACH1 binds to dystrophin and reduces Nav1.5 membrane distribution in cardiomyocytes of lncDACH1 transgenic mice</title>
<p>We firstly validated the binding between lncDACH1 and dystrophin. The RNA pulldown plus immunoblot assay confirmed that lncDACH1 can successfully pulldown dystrophin (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). Conversely, the immunoprecipitation study showed that the antibody for dystrophin precipitated lncDACH1, while the negative control IgG did not (<xref ref-type="fig" rid="fig1">Figure 1B</xref>).</p>
<fig id="fig1" position="float" fig-type="figure">
<label>Figure 1</label>
<caption><title>Binding of lncDACH1 to dystrophin and the effects of cardiomyocyte-specific transgenic overexpression of lncDACH1 (lncDACH1-TG) on the expression and function of sodium channel.</title><p>(A) Blotting of dystrophin pulled-down by lncDACH1. (B) LncDACH1 precipitated by anti-dystrophin antibody. N=4. * P&lt;0.05 vs IgG by one-way ANOVA, followed by Tukey’s post-hoc analysis. (C, D) The total, membrane and cytoplasm levels of dystrophin and Nav1.5 by Western blot. N-cadherin is the loading control for membrane extracts. N=10-11 for total protein; N= 7-14 for membrane protein; N= 8-14 for cytoplasm protein. *P&lt;0.05 versus WT group. *P&lt;0.05 versus WT group. P-values were determined by unpaired t test. (E) Distribution of lncDACH1, dystrophin and Nav1.5 in isolated cardiomyocytes. (F) The mRNA levels of dystrophin and SCN5A. N=8-11. (G) Peak INa currents, I-V curve and kinetics of INa. N=9-15 cells from 3 or more mice. (H) Conduction velocity of perfused hearts by optical mapping recordings. N=7. * P&lt;0.05 versus WT group. P-values were determined by unpaired t test.</p></caption>
<graphic xlink:href="156367v1_fig1.jpg" mimetype="image" mime-subtype="jpeg"/>
</fig>
<p>We next explored the influence of lncDACH1 on cellular distribution of dystrophin. The western blot data showed that the total protein of dystrophin did not change, while the membrane fraction was reduced, and the cytoplasmic fraction increased in the hearts of lncDACH1-TG mice than wild-type (WT) controls (<xref ref-type="fig" rid="fig1">Figure 1C</xref>). Consistently, the membrane and total protein levels of Nav1.5 were reduced, while cytoplasmic Nav1.5 increased in the hearts of lncDACH1-TG mice than WT controls (<xref ref-type="fig" rid="fig1">Figure 1D</xref>). The reduced membrane distribution of dystrophin and Nav1.5 in the cardiomyocytes of lncDACH1-Tg mice was further confirmed by immunofluorescent staining (<xref ref-type="fig" rid="fig1">Figure 1E</xref>). The mRNA levels of dystrophin and SCN5A did not change (<xref ref-type="fig" rid="fig1">Figure 1F</xref>). We then evaluated the functional change of sodium channel. Consistent with reduction of membrane Nav1.5, the peak <italic>I</italic><sub>Na</sub> was significantly decreased in the ventricular myocytes of lncDACH1-TG mice than WT controls, while the kinetics of <italic>I</italic><sub>Na</sub> (activation, inactivation, and recovery) did not change (<xref ref-type="fig" rid="fig1">Figure 1G</xref>). Meanwhile, the conduction velocity was slower in the hearts of lncDACH1-TG than WT mice (<xref ref-type="fig" rid="fig1">Figure 1H</xref>).</p>
<p>We then applied lncDACH1 adenovirus to cultured neonatal cardiomyocytes to confirm the regulation of lncDACH1 on sodium channel <italic>in vitro</italic>. Infection of adenovirus carrying lncDACH1 significantly upregulated the level of lncDACH1 (<xref ref-type="fig" rid="fig2">Figure 2A</xref>) and remarkably inhibited peak <italic>I</italic><sub>Na</sub> with no change in kinetics (<xref ref-type="fig" rid="fig2">Figure 2B, C</xref>). The membrane distribution of dystrophin and Nav1.5 was remarkably reduced by overexpression of lncDACH1 as indicated by immunofluorescent staining (<xref ref-type="fig" rid="fig2">Figure 2D</xref>). The mRNA levels of dystrophin and SCN5A were not altered by lncDACH1 overexpression (<xref ref-type="fig" rid="fig2">Figure 2E</xref>).</p>
<fig id="fig2" position="float" fig-type="figure">
<label>Figure 2</label>
    <caption><title>Effects of lncDACH1 overexpression on sodium channel expression and function in cultured neonatal cardiomyocytes.</title><p>(A) Verification of the expression of lncDACH1 after transfection of adenovirus carrying lncDACH1. N=7-8 from 3 independent cultures. *P&lt;0.05 versus NC (negative control, empty plasmid). P-values were determined by unpaired t test. (B, C) Peak INa currents, I-V curves and kinetics of INa. N=12-16 cells from 3 independent cultures. (D) Distribution of Nav1.5 and dystrophin by immunofluorescent staining. (E) The mRNA levels of dystrophin and SCN5A. N=8-10 from 3 independent cultures.</p></caption>
<graphic xlink:href="156367v1_fig2.jpg" mimetype="image" mime-subtype="jpeg"/>
</fig>
</sec>
<sec id="s2b">
<title>Inhibition of lncDACH1 in cardiomyocytes increased membrane Nav1.5 distribution</title>
<p>We then employed lncDACH1 cardiomyocyte conditional knockout(lncDACH1-CKO) mice to examine the regulation of lncDACH1 on dystrophin and Nav1.5. The western blot data showed that membrane distribution of dystrophin was increased in the hearts of lncDACH1-CKO mice than WT controls, while the total dystrophin protein and dystrophin mRNA did not change (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). Consistently, the membrane and total level of Nav1.5 was increased in the hearts of lncDACH1-CKO mice than WT controls, with no change on SCN5A mRNA (<xref ref-type="fig" rid="fig3">Figure 3B</xref>). The change on dystrophin and Nav1.5 membrane distribution was further validated by immunofluorescent staining (<xref ref-type="fig" rid="fig3">Figure 3C</xref>). Meanwhile, the peak <italic>I</italic><sub>Na</sub> was larger in cardiomyocytes of lncDACH1-CKO mice than WT controls, while the kinetics of <italic>I</italic><sub>Na</sub> (activation, inactivation, and recovery) did not change (<xref ref-type="fig" rid="fig3">Figure 3D</xref>). Consistent with the increase of peak <italic>I</italic><sub>Na</sub>, the conduction velocity in the hearts of lncDACH1-CKO mice was faster than WT controls (<xref ref-type="fig" rid="fig3">Figure 3E</xref>).</p>
<fig id="fig3" position="float" fig-type="figure">
<label>Figure 3</label>
    <caption><title>Conditional knockout of lncDACH1(lncDACH1-cKO) in cardiomyocytes increased peak sodium current, membrane Nav1.5 expression.</title><p>(A) The total, membrane and cytoplasm levels of dystrophin by Western blot and dystrophin mRNA by qRT-PCR. N-cadherin is the loading control for membrane extracts. N=10 for total protein; N= 10 for membrane protein; N= 15 for cytoplasm protein. *P&lt;0.05 versus WT group. P-values were determined by unpaired t test. (B) The total, membrane and cytoplasm levels of Nav1.5 by Western blot and SCN5A mRNA by qRT-PCR. N-cadherin is the loading control for membrane extracts. N=10 for total protein; N= 8 for membrane protein; N= 8 for cytoplasm protein. *P&lt;0.05 versus WT group. P-values were determined by unpaired t test. (C) Distribution of lncDACH1, dystrophin and Nav1.5 in isolated cardiomyocytes. (D) Peak INa currents, I-V curve and kinetics of INa. N=10-15 cells from 3 or more mice. (E) Conduction velocity of perfused hearts by optical mapping recordings. N=7 and 5. * P&lt;0.05 versus WT group. P-values were determined by unpaired t test.</p></caption>
<graphic xlink:href="156367v1_fig3.jpg" mimetype="image" mime-subtype="jpeg"/>
</fig>
<p>We further confirmed effects of lncDACH1 knockdown with its siRNAs on sodium channel in cultured neonatal cardiomyocytes <italic>in vitro</italic>. Infection of adenovirus carrying siRNAs for lncDACH1 significantly reduced the level of lncDACH1 (<xref ref-type="fig" rid="fig4">Figure 4A</xref>). The patch-clamp recordings showed that knockdown of lncDACH1 significantly increased the current density of peak <italic>I</italic><sub>Na</sub> with no change on channel kinetics (<xref ref-type="fig" rid="fig4">Figure 4B, C</xref>). Membrane distribution of dystrophin and Nav1.5 were both increased after knockdown of lncDACH1 as indicated by immunofluorescent staining (<xref ref-type="fig" rid="fig4">Figure 4D</xref>). The mRNA levels of dystrophin and SCN5A were not altered by lncDACH1 knockdown (<xref ref-type="fig" rid="fig4">Figure 4E</xref>).</p>
<fig id="fig4" position="float" fig-type="figure">
<label>Figure 4</label>
    <caption><title>Effects of lncDACH1 knockdown on sodium channel expression and function in cultured neonatal cardiomyocytes.</title><p>(A) Verification of the expression of lncDACH1 after infection of adenovirus carrying lncDACH1 siRNAs. N=15 from 3 independent cultures. *P&lt;0.05 versus NC (negative control, empty plasmids). P-values were determined by unpaired t test. (B, C) Peak INa currents, I-V curve and kinetics of INa. N=9-15 from 3 independent cultures. (D) Distribution of Nav1.5 and dystrophin by immunofluorescent staining. (E) The mRNA levels of dystrophin and SCN5A. N=11-15 from 3 independent cultures.</p></caption>
<graphic xlink:href="156367v1_fig4.jpg" mimetype="image" mime-subtype="jpeg"/>
</fig>
</sec>
<sec id="s2c">
<title>Transgenic overexpression of lncDACH1 is arrhythmogenic in mice</title>
<p>We next evaluated whether the inhibition of Nav1.5 by lncDACH1 is arrhythmogenic in lncDACH1-TG mice. Electrical pacing technique was employed to evaluate the arrhythmia susceptibility of intact hearts <italic>in vivo</italic> and isolated hearts <italic>ex vivo</italic>. The <italic>in vivo</italic> study showed that programmed pacing induced more ventricular arrhythmia in lncDACH1-TG mice that WT controls. Both induction rate and episodes of ventricular arrhythmia were higher in lncDACH1-TG mice (<xref ref-type="fig" rid="fig5">Figure 5A</xref>). In consistent, the <italic>ex vivo</italic> electrical pacing study demonstrated that ventricular arrhythmia was more frequently occurred in lncDACH1-Tg mice (<xref ref-type="fig" rid="fig5">Figure 5B</xref>). The optimal mapping study revealed that there are more breaking points in the perfused heart of lncDACH1-TG mice than WT controls (<xref ref-type="fig" rid="fig5">Figure 5C-E</xref>). Conversely, no ventricular arrhythmia was induced in the hearts of lncDACH1-CKO mice (<xref ref-type="fig" rid="fig5">Figure 5F</xref>).</p>
<fig id="fig5" position="float" fig-type="figure">
<label>Figure 5</label>
    <caption><title>Increased arrhythmia susceptibility in lncDACH1-TG mice.</title><p>(A) Ventricular fibrillation (VF) induced by S1S2 pacing in intact mice. N=10-16.( B) Ventricular fibrillation (VF) induced by S1S1 pacing of perfused hearts.(C) Break points during VT of WT and lncDACH1-TG mice by optical mapping. Consecutive phase maps sampled at 10-ms interval during VF from WT and TG mice. Phase singularities (wavebreaks) are indicated by phase maps. Upper panels showed corresponding optical recording of VF at asterisk site. n=8. (D) Representative of dorminant frequency of VF from WT and TG mice. (E) The number of phase singularities and dorminant frequency of WT and TG mice. (F) Ventricular fibrillation (VF) induced by S1S1 pacing in perfused hearts. N=5-7 mice.</p></caption>
<graphic xlink:href="156367v1_fig5.jpg" mimetype="image" mime-subtype="jpeg"/>
</fig>
</sec>
<sec id="s2d">
<title>The conservative fragment of lncDACH1 reduced peak sodium current and promoted ventricular arrhythmia</title>
<p>The sequence blasting data showed that the fragment of lncDACH1 from 835 to 2085 nts is conservative between human and mouse. We then cut lncDACH1 into different fragments (<xref ref-type="fig" rid="fig6">Figure 6A</xref>) to evaluate the sequence that is responsible for the binding with dystrophin. The data showed that only fragments containing the conserved sequence, fragments a and b, can pulldown dystrophin, indicating that the conserved sequence may be the functional region of lncDACH1 (<xref ref-type="fig" rid="fig6">Figure 6A</xref>).</p>
<fig id="fig6" position="float" fig-type="figure">
<label>Figure 6</label>
    <caption><title>The conserved fragment of lncDACH1(cF-lncDACH1) inhibited sodium channel function in mice.</title><p>(A) Pulldown of dystrophin by fragments of lncDACH1 as indicated. (B) Verification of the expression of cF-lncDACH1 after injection of adeno-virus carrying cF-lncDACH1. N=5. *P&lt;0.05 versus NC (negative control, Adeno-virus carrying empty plasmid). P-values were determined by unpaired t test. (C) The total, membrane and cytoplasm levels of dystrophin and Nav1.5 by Western blot. N-cadherin is the loading control for membrane extracts. N=11-12 for total protein; N= 10 for membrane protein; N= 5-11 for cytoplasm protein. *P&lt;0.05 versus NC group. P-values were determined by unpaired t test. (D) Distribution of dystrophin and Nav1.5 in isolated cardiomyocytes. (E) Representative traces and I-V curve of peak INa currents. N=12-15 from 3 or more mice. (F) Conduction velocity of perfused hearts by optical mapping recordings. N=9-10. * P&lt;0.05 versus NC group. P-values were determined by unpaired t test. (G) Break points during VT by optical mapping. H. Ventricular (VF) induced by S1S2 pacing in intact mice.</p></caption>
<graphic xlink:href="156367v1_fig6.jpg" mimetype="image" mime-subtype="jpeg"/>
</fig>
<p>We then examined the influence of the conserved sequence from 835 to 2085 nts (conserved fragment of lncDACH1, cF-lncDACH1) on cardiac sodium channel. The adenovirus carrying cF-lncDACH1 was constructed and administered to mice. The successful overexpression of cF-lncDACH1 was validated by qRT-PCR (<xref ref-type="fig" rid="fig6">Figure 6B</xref>). Administration of cF-lncDACH1 reduced the membrane distribution, and increased cytoplasmic expression of both dystrophin and Nav1.5 as indicated by western blot and immunofluorescent data (<xref ref-type="fig" rid="fig6">Figure 6C, D</xref>). The mRNA levels of dystrophin and Nav1.5 were not affected by cF-lncDACH1 (<xref ref-type="supplementary-material" rid="data1">Supplemental Figure 1A</xref>). Overexpression of cF-lncDACH1 reduced peak <italic>I</italic><sub>Na</sub> currents (<xref ref-type="fig" rid="fig6">Figure 6E</xref>), and produced no influence on channel kinetics (<xref ref-type="supplementary-material" rid="data1">Supplemental Figure 1B</xref>). The optical mapping data showed that administration of cF-lncDACH1 reduced conduction velocity and increased break points of ventricular arrhythmias (<xref ref-type="fig" rid="fig6">Figure 6F, G</xref>). The induction rate and episodes of ventricular tachycardia (VT) were higher in cF-lncDACH1 group than controls (<xref ref-type="fig" rid="fig6">Figure 6H</xref>).</p>
<p>In cultured neonatal cardiomyocytes, overexpression of cF-lncDACH1 reduced peak <italic>I</italic><sub>Na</sub> with no change in kinetics, inhibited membrane distribution of dystrophin and Nav1.5, and produced no influence on the mRNA levels of dystrophin and SCN5A (<xref ref-type="supplementary-material" rid="data2">Supplemental Figure 2</xref>).</p>
</sec>
<sec id="s2e">
<title>Activation of dystrophin transcription by dCas9-SAM system prevented the reduction of sodium current in lncDACH1 transgenic mice</title>
<p>As lncDACH1 reduced Nav1.5 membrane targeting by interacting with dystrophin, we reasoned that overexpression of dystrophin may rescue the inhibition of Nav1.5 by lncDACH1. To test this notion, we constructed the AAV9 virus carrying dCas9-SAM system that can activate dystrophin transcription (AAV9-Dys-Act) to perform rescuing experiments on lncDACH1-TG mice (<xref ref-type="supplementary-material" rid="data3">Supplemental Figure 3</xref>). Tail vein injection of AAV9-Dys-Act virus significantly increased the mRNA level of dystrophin in the hearts of both WT and lncDACH1-TG mice (<xref ref-type="fig" rid="fig7">Figure 7A</xref>). The western blot data showed that overexpression of dystrophin with AAV9-Dys-Act virus increased both total and membrane protein expression of dystrophin, and rescued the reduction of dystrophin expression in lnDACH1-Tg mice (<xref ref-type="fig" rid="fig7">Figure 7A</xref>). The mRNA level of SCN5A was not influenced by AAV9-Dys-Act virus (<xref ref-type="fig" rid="fig7">Figure 7B</xref>). Strikingly, AAV9-Dys-Act virus administration restored total and membrane expression of Nav1.5 in lnDACH1-TG mice (<xref ref-type="fig" rid="fig7">Figure 7B</xref>). In addition, AAV9-Dys-Act virus injection rescued the reduction of peak <italic>I</italic><sub>Na</sub> current in lnDACH1-TG mice (<xref ref-type="fig" rid="fig7">Figure 7C</xref>). The kinetics of <italic>I</italic><sub>Na</sub> current did not change among groups (<xref ref-type="fig" rid="fig7">Figure 7C</xref>). Activation of dystrophin transcription with AAV9-Dys-Act virus restored the conduction velocity in lncDACH1-TG mice (<xref ref-type="fig" rid="fig7">Figure 7D</xref>).</p>
<fig id="fig7" position="float" fig-type="figure">
<label>Figure 7</label>
    <caption><title>Activation of dystrophin transcription by AAV9 virus carrying dCas9-SAM system (AAV9-Dys-Act) rescued the remodeling of sodium channel in lncDACH1-TG mice.</title><p>(A) The mRNA level of dystrophin by real-time PCR (N=12-17) and the total, membrane and cytoplasm protein levels of dystrophin by western blot. N-cadherin is the loading control for membrane extracts. N=7 for total protein; N= 8 for membrane protein; N= 8 for cytoplasm protein. *P&lt;0.05 versus NC group. NC, AAV9 virus carrying dCas9-SAM system with control sgRNA; Dys, AAV9 virus carrying dCas9-SAM system with sgRNA targeting dystrophin promoter. (B) The mRNA level of Nav1.5 by real-time PCR (N=10-12) and the total, membrane and cytoplasm protein levels of Nav1.5 by western blot. N-cadherin is the loading control for membrane extracts. N=10 for total protein; N= 5 for membrane protein; N= 6 for cytoplasm protein. *P&lt;0.05 versus NC group. (C) Representative traces, I-V curves and kinetics of peak INa currents. N=11-20 cells from 3 or more mice. (D) Conduction velocity of perfused hearts by optical mapping recordings. N=6-9. * P&lt;0.05 versus NC group. P-values were determined by unpaired t test. (E) Ventricular fibrillation (VF) induced by S1S1 pacing in perfused hearts. N= 7-10. (F) Ventricular fibrillation (VF) induced by S1S2 pacing in intact mice. N= 10-13. The data are analyzed by one-way ANOVA followed by Tukey’s post-hoc analysis.</p></caption>
<graphic xlink:href="156367v1_fig7.jpg" mimetype="image" mime-subtype="jpeg"/>
</fig>
<p>Both <italic>in vivo</italic> and <italic>ex vivo</italic> data indicated that activation of dystrophin transcription reduced the susceptibility to ventricular arrhythmia of lncDACH1-TG mice (<xref ref-type="fig" rid="fig7">Figure 7E, F</xref>).</p>
</sec>
<sec id="s2f">
<title>Hadhb binds to lncDACH1 and promotes its decay</title>
<p>Reduced Nav1.5 expression and reduction of peak <italic>I</italic><sub>Na</sub> in heart failure have been reported by a bunch of studies<sup><xref ref-type="bibr" rid="c15">15</xref>, <xref ref-type="bibr" rid="c16">16</xref>, <xref ref-type="bibr" rid="c17">17</xref>, <xref ref-type="bibr" rid="c18">18</xref></sup>. We therefore evaluated the contribution of lncDACH1 on sodium channel remodeling in transaortic constriction (TAC) induced heart failure model in mice. We found that lncDACH1 was increased in failing hearts than sham controls (<xref ref-type="fig" rid="fig8">Figure 8A</xref>). Although lncDACH1 was upregulated in failing hearts, the mRNA of its host gene DACH1 did not change (<xref ref-type="fig" rid="fig8">Figure 8B</xref>). This finding excluded the transcription related mechanism on lncDACH1 upregulation during heart failure. By analyzing the RNA Pulldown plus Mass Spectrometry data, we identified three potential interacting proteins of lncDACH1 that have been shown to regulate RNA stability. They are ANP32a (acidic leucine-rich nuclear phosphoprotein 32A), eIF4A1(eukaryotic initiation factor 4A1) and hydroxyacyl-CoA dehydrogenase subunit beta (hadhb). We therefore speculated that it may be the change of RNA stability that renders to the expression change of lncDACH1. We then tested whether these proteins can affect lncDACH1 level by knocking down their expression with siRNA. The data showed that knockdown of hadhb increased the expression of lncDACH1, while knockdown of ANP32a and eIF4A1 produced no influence (<xref ref-type="fig" rid="fig8">Figure 8C</xref>). The influence of hadhb on lncDACH1 stability was further validated by the fact that knockdown of hadhb increased the decaying half-life of lncDACH1(<xref ref-type="fig" rid="fig8">Figure 8D</xref>). Furthermore, the sense sequence of lncDACH1 successfully pulled down hadhb, and the antibody of hadhb precipitated lncDACH1(<xref ref-type="fig" rid="fig8">Figure 8E</xref>). Additionally, the protein level of hadhb was reduced in mouse failing hearts (<xref ref-type="fig" rid="fig8">Figure 8F</xref>), which is inversely correlated to the upregulation of lncDACH1. The siRNA for hadhb reduced the expression of Nav1.5 (<xref ref-type="fig" rid="fig8">Figure 8G</xref>). These data indicated that hadhb is an upstream regulator of lncDACH1 which determines the stability of lncDACH1.</p>
<fig id="fig8" position="float" fig-type="figure">
<label>Figure 8</label>
    <caption><title>Hadhb binds to lncDACH1 and promotes its decay.</title><p>(A) The expression level of lncDACH1 in the hearts of TAC mice. N=5-8. * P&lt;0.05 by unpaired t test. (B) The mRNA level of DACH1 in the hearts of TAC mice. N=12-14. (C) Effects of siRNAs for anp32a, eif4a1 and hadhb on the expression of lncDACH1. N=5-12 from 3 independent cultures. * P&lt;0.05 by unpaired t test. (D) The effects of hadhb siRNA on the decay of lncDACH1. N=6-15 from 3 independent cultures. (E) The effects of hadhb siRNA on the protein expression of Nav1.5 and dystrophin. (F) Blotting of hadhb pulled-down by lncDACH1, and precipitation of lncDACH1 by anti-hadhb antibody. N=4. * P&lt;0.05 vs IgG by one-way ANOVA followed by Tukey’s post-hoc analysis. (G) LncDACH1 inhibits Nav1.5 in human iPS differentiated cardiomyocytes. I. Schematic summary of the signaling pathway of hadhb/lncDACH1/dystrophin/Nav1.5.</p></caption>
<graphic xlink:href="156367v1_fig8.jpg" mimetype="image" mime-subtype="jpeg"/>
</fig>
<p>We lastly evaluated the human conserved sequence of lncDACH1(hcF-lncDACH1) on Nav1.5 distribution of human iPS induced cardiomyocytes. We found that overexpression of hcF-lncDACH1 reduced the membrane distribution of dystrophin and Nav1.5 (<xref ref-type="fig" rid="fig8">Figure 8H</xref>).</p>
</sec>
</sec>
<sec id="s3" sec-type="discussion">
<title>Discussion</title>
<p>In this study, we discovered that lncDACH1 is critical regulator of sodium channel in the heart. LncDACH1 binds to dystrophin and thus inhibits membrane trafficking of Nav1.5, which leads to the reduction of peak sodium current and impairment of cardiac conduction. Therefore, upregulation of lncDACH1 increased the susceptibility to ventricular arrhythmia (<xref ref-type="fig" rid="fig8">Fig 8I</xref>).</p>
<p>LncRNAs have been established to be critical regulators of various biological processes<sup><xref ref-type="bibr" rid="c19">19</xref></sup>. The action modes of lncRNAs are complex. One major mechanism for them to exert their biological function in the cytoplasm is to interact with the molecules such as proteins, miRNAs, mRNAs to alter protein translation, enzyme activity, protein degradation, etc<sup><xref ref-type="bibr" rid="c20">20</xref></sup>. For instance, lncRNA- CCRR was shown to inhibit the endocytic trafficking of connexin-43 by binding to CIP85<sup><xref ref-type="bibr" rid="c12">12</xref></sup>. LncDACH1 mainly distributes in the cytoplasm, and can bind to SERCA2a to promote its ubiquitination and degradation<sup><xref ref-type="bibr" rid="c13">13</xref></sup>. LncDACH1 can also bind to protein phosphatase 1 catalytic subunit alpha (PP1A) to inhibit its dephosphorylation activity on yes-associated protein 1 (YAP1), leading to the cytoplasmic sequestration of YAP1<sup><xref ref-type="bibr" rid="c14">14</xref></sup>. The unraveling of the molecular mechanism of Nav1.5 expression and function is critical for the insightful understanding of sodium channel function under physiological and pathological conditions. Several interacting proteins have been demonstrated to determine membrane distribution of Nav1.5 and sodium channel function<sup><xref ref-type="bibr" rid="c4">4</xref></sup>. Dystrophin is a well-characterized Nav1.5 partner protein. It indirectly interacts with Nav1.5 via syntrophin, which binds with the C-terminus of dystrophin and with the SIV motif on the C-terminus of Nav1.5<sup><xref ref-type="bibr" rid="c6">6</xref>, <xref ref-type="bibr" rid="c21">21</xref></sup>. In this study, we found that lncDACH1 binds to dystrophin and leads to the impairment of Nav1.5 trafficking and reduced membrane distribution. This is so far the first evidence verifying the regulation of lncRNA on cardiac sodium channel.</p>
<p>Although the membrane distribution of both dystrophin and Nav1.5 was inhibited by lncDACH1, the total protein level of dystrophin was not affected, while Nav1.5 was reduced. The mechanism for the differential influence of lncDACH1 on total protein levels of dystrophin and Nav1.5 is unclear. One explanation may be that Nav1.5 is a membrane channel protein. If they failed to target on the plasma membrane, they may be regarded as unnecessary protein and undergo the process of protein degradation. The E1-E3 enzymes in the ubiquitination systems have been shown to regulate the degradation of Nav1.5, which includes E1 enzyme UBE1(Ubiquitin-activating Enzyme1), UBA6(Ubiquitin-like modifier-activating enzyme 6), E2 enzyme, UBC9 (Ubiquitin-Conjugating Enzyme 9), and E3 ligase Nedd4-2 (neuronal precursor cell expressed developmentally downregulated 4-2)<sup><xref ref-type="bibr" rid="c22">22</xref>, <xref ref-type="bibr" rid="c23">23</xref>, <xref ref-type="bibr" rid="c24">24</xref></sup>. LITAF (lipopolysaccharide-induced tumor necrosis factor-alpha factor), a protein encoding a regulator of endosomal trafficking, was shown to reduce surface Nav1.5 by promoting degradation of NEDD4-2<sup><xref ref-type="bibr" rid="c25">25</xref></sup>. Therefore, cytoplasmic Nav1.5 that failed to target on plasma membrane may be quickly distinguished and then degraded by these ubiquitination enzymes.</p>
<p>The dysfunction of sodium channel is associated with various arrhythmias. Reduced peak <italic>I</italic><sub>Na</sub> due to SCN5A loss-of-function mutation can cause a series of arrhythmias such as atrial fibrillation, Brugada syndrome, long QT syndrome, sudden cardiac death, and ventricular tachycardia etc<sup><xref ref-type="bibr" rid="c26">26</xref>, <xref ref-type="bibr" rid="c27">27</xref></sup>. Consistently, we found that accompanied with the reduction of peak <italic>I</italic><sub>Na</sub>, overexpression of lncDACH1 reduced ventricular conduction velocity and increased the susceptibility to ventricular arrhythmia in mice. The increased peak <italic>I</italic><sub>Na</sub> due to SCN5A gain-of-function mutation is associated arrhythmias such as atrial fibrillation, long QT syndrome; polymorphic ventricular complexes and ventricular arrhythmia<sup><xref ref-type="bibr" rid="c26">26</xref>, <xref ref-type="bibr" rid="c27">27</xref></sup>. In this study, although the peak <italic>I</italic><sub>Na</sub> increased in lncDACH1-CKO mice, the susceptibility to arrhythmia did not increase. One difference of our data with SCN5A gain-of-function mutation is that the kinetics of peak <italic>I</italic><sub>Na</sub> often change during mutation, while it is not the case of lncDACH1 knockout. One possible explanation may be that the increase of peak <italic>I</italic><sub>Na</sub> has not reach the limit to break the electrophysiological balance of the heart.</p>
<p>Sodium channel remodeling is commonly occurred in cardiac diseases especially heart failure. Despite of some discrepancy, the main observations are that the peak <italic>I</italic><sub>Na</sub>, SCN5A mRNA and Nav1.5 protein are reduced during heart failure of both human patients and animal models <sup><xref ref-type="bibr" rid="c15">15</xref>, <xref ref-type="bibr" rid="c16">16</xref>, <xref ref-type="bibr" rid="c17">17</xref>, <xref ref-type="bibr" rid="c18">18</xref></sup>. In this study, we found that lncDACH1 was increased during heart failure, indicating that it may contribute to sodium channel remodeling and arrhythmogenesis during heart failure by interfering the action of dystrophin. Interestingly, we found that activation of dystrophin with dCas9-SAM system restored the membrane distribution of Nav1.5 in cardiomyocytes of lncDACH1-TG mice, which implies its potential in counteracting sodium channel remodeling of patients with heart failure.</p>
<p>The low sequence conservation of lncRNAs among species is a critical issue that limits the extrapolation of data from animal studies to human beings<sup><xref ref-type="bibr" rid="c28">28</xref>, <xref ref-type="bibr" rid="c29">29</xref></sup>. In this study, we found that the conserved fragment of lncDACH1 exhibits the same effect as lncDACH1 on Nav1.5 trafficking and arrhythmogenesis. Moreover, the human conservative homologous fragment of lncDACH1 can inhibit the membrane distribution of Nav1.5 in cardiomyocytes derived from induced pluripotent stem cells (iPS-CMs). These findings hint the clinical relevance of lncDACH1, which holds the potential to become a therapeutic target for treating sodium channel remodeling in clinic.</p>
<p>In conclusion, lncDACH1 is a novel regulator of sodium channel, which suppresses the membrane trafficking of Nav1.5 by disturbing the function of dystrophin. The current work enriched our understanding of the biology of sodium channel trafficking and function, and indicated that lncRNAs possess the potential to become therapeutic targets for ventricular arrhythmias.</p>
</sec>
<sec id="s4" sec-type="methods">
<title>Methods</title>
<sec id="s4a">
<title>Animals</title>
<p>Neonatal (within 3-day post born) and adult C57BL/6 mice (8 to 10 weeks old) were provided by the animal center at the Second Affiliated Hospital of Harbin Medical University. Use of animals was approved by the Ethic Committees of Harbin Medical University and conformed to the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication No. 85-23, revised 1996).</p>
</sec>
<sec id="s4b">
<title>Neonatal cardiomyocytes preparation</title>
<p>Neonatal cardiomyocytes were isolated from 3-day-old mice in accordance with the following procedures. Briefly, after dissection, hearts were washed and minced in 0.25% trypsin. Pooled cell suspensions were centrifuged and resuspended in Dulbecco’s modified Eagle’s medium (DMEM Hyclone, USA) supplemented with 10% fetal bovine serum, 100 U/ml penicillin and 100 μg/ml streptomycin. The suspension was incubated in culture flasks for 90 min, which makes fibroblasts preferentially adhere to the bottom of the culture flasks. Neonatal cardiomyocytes were removed from the culture flasks and the medium was changed. Cell cultures were incubated for 48 h at 37 °C in a humidified atmosphere of 95% oxygen and 5% carbon dioxide before any experimentation.</p>
</sec>
<sec id="s4c">
<title>Generation of cardiac myocyte-specific lncDACH1 overexpressing mice</title>
<p>Cardiomyocyte-specific lncDACH1 overexpressing mice driven by murine αMHC promoter on a C57BL/6 background was generated by Biocytogen Co., Ltd (Beijing, China) as demonstrated in previous study<sup><xref ref-type="bibr" rid="c13">13</xref></sup>.</p>
</sec>
<sec id="s4d">
<title>Generation of cardiomyocyte-specific lncDACH1 knockout mice</title>
<p>LncDACH1 conditional KO mice (lncDACH1 Flox/Flox) was generated by using CRISPR/Cas9 technique on C57BL/6 background mice by Biocytogen Co., Ltd (Beijing, China) as demonstrated in previous study<sup><xref ref-type="bibr" rid="c13">13</xref></sup>.</p>
</sec>
<sec id="s4e">
<title>Construction of adeno-associated virus 9 (AAV9) carrying deactivated clustered regularly interspaced short palindromic repeats associated protein 9 nuclease- synergistic activation mediator(dCas9-SAM) system to activate the transcription of dystrophin</title>
<p>Adeno-associated virus 9(AAV9) carrying dCas9-SAM system to activate the transcription of dystrophin was constructed as reported previously with brief modifications<sup><xref ref-type="bibr" rid="c30">30</xref></sup>. The sgRNA targeting on the promoter region of dystrophin was designed and cloned into the multiple cloning site of plasmid GV639 (EFS-NLS-dSaCas9-NLS-VP64-bGHpA-U6). The constructed plasmid was packaged into AAV9 virus. The sequence of sgRNA is: 5′- CGCTTCCGCGGCCCGTTCAA -3′; The mock-sgRNA target sequence (5′- CGCTTCCGCGGCCCGTTCAA -3′) was used as negative control. The obtained AAV9 virus volume was administered into C57BL/6 mice via tail vein injection at 1×10<sup><xref ref-type="bibr" rid="c11">11</xref></sup> genome containing particles (GC)/animal in 100μl.</p>
</sec>
<sec id="s4f">
<title>Construction of adenovirus carrying cF-lncDACH1 and in vivo gene delivery</title>
<p>Adenovirus vectors carrying cF-lncDACH1(OE- cF-lncDACH1) and a negative control (NC) and a CAG promoter conjugated with green fluorescent protein (GFP) were constructed by Genechem Co., Ltd. (Shanghai, China). OE- cF-lncDACH1, control constructs at 1×10<sup>9</sup> genome containing particles (GC)/animal in 100μl volume was administered into C57BL/6 mice with body weights ranging from 18~22g via tail vein injection. Seventy-two hours after injection, the mice were subjected to further study.</p>
</sec>
<sec id="s4g">
<title>Construction of adenovirus carrying lncDACH1, lncDACH1 siRNA, conserved fragment of human lncDACH1 and infection</title>
<p>Adenovirus vectors carrying lncDACH1(OE-lncDACH1), a short RNA fragment for silencing lncDACH1 (Si-lncDACH1) or conserved fragment of human lncDACH1(hcF-lncDACH1) and a CAG promoter conjugated with green fluorescent protein (GFP) were constructed by Genechem Co., Ltd. (Shanghai, China). Neonatal cardiomyocytes were infected with adenovirus for 48 hours, and then subjected to subsequent study.</p>
</sec>
<sec id="s4h">
<title>Transfection of Hadhb, Eif4a1, and Anp32 siRNA</title>
<p>siRNA for Hadhb (siHadhb), Eif4a1(siEif4a1), Anp32(siAnp32) and a scrambled negative control RNA (siNC) were synthesized by Generalbiol (Chuzhou, Anhui, China). These siRNAs were transfected at a final concentration of 100 nM into NMVMs using the X-treme GENE Transfection Reagent (Roche, Indianapolis, USA) according to the manufacturer’s protocols. The cardiomyocytes were collected for total RNA isolation or protein purification. The sequences are: siHadhb, sense 5′- GCUCUCAGAUCUUCUAUAATT-3′ and antisense 5′- UUAUAGAAGAUCUGAGAGCTT-3′; siEif4a1, sense 5′- GCUCACCGAGAAGAUGCAUTT-3′ and antisense 5′- UUAUAGAAGAUCUGAGAGCTT-3′; siAnp32, sense 5′- GCCUCACCUCCAUUUCCAATT-3′ and antisense 5′- UUGGAAAUGGAGGUGAGGCTT-3′.</p>
</sec>
<sec id="s4i">
<title>Induction of ventricular arrhythmia</title>
<p>C57BL/6 mice were anesthetized with 2,2,2-tribromoethanol (200 mg/kg, i.p.). An octapolar electrophysiological catheter (1.1F, SciSense Inc., Canada) was inserted into the right ventricle via the jugular vein. Intracardiac pacing was performed using an automated stimulator interfaced with the data acquisition system (GY6000; HeNan HuaNan Medical Science &amp; Technology Ltd., Zhengzhou, China). The surface recording electrode was fixed on LV epicardium to record pseudo-ECG. Inducibility of ventricular tachycardia (VT) was determined by applying a train of ten consecutive electrical pulses with a coupling interval of 80 ms (S1), followed by two extra stimuli (S2 and S3) at coupling intervals of 2 ms, respectively. Successful induction of VT was defined as the appearance of rapid nonsinus rhythm ventricular activations lasting for three beats or more.</p>
</sec>
<sec id="s4j">
<title>Optical mapping recording</title>
<p>Mice were heparinized and euthanized by 2,2,2-tribromoethanol (200 mg/kg, intraperitoneal injection; Sigma, St Louis, MO, USA). The heart was isolated and langendorff perfused with Tyrode’s solution (NaCl 128.2 mM, CaCl<sub>2</sub>•2H<sub>2</sub>O 1.3 mM, KCl 4.7 mM, MgCl<sub>2</sub>•6H<sub>2</sub>O 1.85 mM, NaH<sub>2</sub>PO<sub>4</sub>•2H<sub>2</sub>O 1.19 mM, Na<sub>2</sub>CO3 20 mM, and glucose 11.1 mM; pH 7.35) at 37 °C. After 10 min of stabilization, the hearts were stained with RH237 (10 μM) for membrane voltage (Vm) mapping. The dye was excited at 710 nm using monochromatic light-emitting device. The fluorescence was filtered and recorded simultaneously with a MiCAM05 CMOS camera (SciMedia, USA) at 1ms/frame and 100x100 pixels with a spatial resolution of 0.35×0.35 mm<sup>2</sup> per pixel. Blebbistatin (10 μM, Selleckchem, Houston, TX, USA) was used to inhibit motion artifact during optical mapping.</p>
</sec>
<sec id="s4k">
<title>Experimental protocol of optical mapping</title>
<p>A pair of hook bipolar electrodes was inserted into apex of heart for pacing. A pseudo-ECG was obtained with widely spaced bipolar electrodes to determine ventricular rhythm. The ventricles were initially paced at a constant pacing cycle length (PCL) of 200ms. The PCLs were progressively shortened (200, 100, 60, 40, 30, 20ms) with a duration of 1-2 s until ventricular tachycardia (VT) was induced or the loss of 1:1 capture of the ventricles. Optical recording was performed after 20 beats of stable pacing at each PCL. Optical recordings were then performed during VT.</p>
</sec>
<sec id="s4l">
<title>Patch-clamp recording</title>
<p>Whole-cell configuration of the patch-clamp technique was used to record peak <italic>I</italic><sub>Na</sub>. Experiments were performed at room temperature (22~23°C) by using a MultiClamp 700B (Alembic Instruments) amplifier. Pipettes (tip resistance 1 to 2 MΩ) were filled with a solution containing (in mM): NaCl 5, CaCl<sub>2</sub> 2, MgCl<sub>2</sub> 2, CsCl 130, HEPES 10, EGTA 15 and MgATP 4 (pH 7.2 with CsOH). Myocytes were bathed with a solution containing (in mM): NaCl 25, CaCl<sub>2</sub> 2, MgCl<sub>2</sub> 2.5, CsCl 108.5, HEPES 10, CoCl<sub>2</sub> 2.5 and glucose 10 (pH 7.4 with CsOH).</p>
</sec>
<sec id="s4m">
<title>Differentiation of human induced pluripotent stem cells(hiPSCs) to cardiomyocytes</title>
<p>Undifferentiated hiPS cells (AC-iPSC) were cultured on Matrigel-coated plates in an E8 medium (CA1001500, CELLAPY). Differentiation basal medium composed of RPMI1640 medium (C11875500BT, Thermo Fisher Scientific) and B27 minus insulin (A1895601, Thermo Fisher Scientific) was used to induce cardiomyocyte differentiation. Specifically, the 70~80% confluent hiPSCs were incubated in differentiation basal medium added with CHIR-99021 (HY-10182, MCE) for 1 day and Wnt-C59 (S7037, Selleck Chemicals) for 2 days. Then, the cells were cultured in RPMI1640 basal medium containing B27 (17504044, Thermo Fisher Scientific), which was replaced with fresh medium every 1~2 days. Beating cells were observed after 8 days of differentiation induction and used for further study.</p>
</sec>
<sec id="s4n">
<title>Construction of truncated LncDACH1 fragment plasmids</title>
<p>The sequence of lncDACH1 was divided into five fragments. The cDNA of each fragment was inserted into the pCDNA3.1, respectively. The first 417 nts of the entire sequences was cut off and constructed as fragment-a (418-2085 nts). Another 417 nts was cut off to generate fragment-b (835-2085 nts). The third 417 nts was cut off to generate fragment-c (1251-2085 nts). Fragment-d is from 835-1668 nts, and fragment-e is from 835-1251 nts.</p>
</sec>
<sec id="s4o">
<title>Isolation of cardiac myocytes</title>
<p>Hearts were rapidly excised, cannulated, and perfused with Ca<sup>2+</sup> -free Tyrode solution (in mM): NaCl 137, KCl 5.4, NaH<sub>2</sub>PO<sub>4</sub> 0.16, glucose 10, CaCl<sub>2</sub> 1.8, MgCl<sub>2</sub> 0.5, HEPES 5.0, and NaHCO<sub>3</sub> 3.0 (pH 7.4 adjusted with NaOH) for 5 min. The heart was then perfused with a solution containing collagenases B and D (Roche) and protease XIV (Sigma) until digestion was complete. Tissue was dissociated using forceps, and dissociated left ventricular cardiomyocytes were gradually exposed to Ca<sup>2+</sup> (from 50 to 500 μM over 40 min) and plated in culture chambers for further studies.</p>
</sec>
<sec id="s4p">
<title>Immunocytochemistry of isolated mouse ventricular myocytes</title>
<p>Cardiomyocytes were fixed for 10 min with 4% paraformaldehyde in PBS, and then washed in PBS for 10 min (2 times). The cells were permeabilized with 0.5% Tween 20 for 30 min. After washed out with PBS for 10 min (3 times), cardiomyocytes were incubated with primary antibodies against Nav1.5 (ASC005, Alomone, 1;200) and dystrophin (MANDYS8, SIGMA, 1;300) overnight at 4°C. Following washout with PBS (10 min, 3 times), cells were incubated with secondary antibodies for 1h and washed with PBS (10 min, 3 times). The cover slips were mounted onto frosted slides in a solution composed of 90% FluorSave Reagent (Calbiochem, La Jolla, CA, USA) and 10% 10X PBS.</p>
</sec>
<sec id="s4q">
<title>Fluorescent in situ hybridization (FISH)</title>
<p>In situ hybridization was performed with a Fluorescent in Situ Hybridization (FISH) Kit (RiboBio, Guangzhou, China). Briefly, isolated cardiomyocytes were fixed in 4% formaldehyde at 4°C for 10 min and dried out on the slides at room temperature (RT). The slides were rinsed and permeabilized with 0.5% Triton-100 in PBS at RT for 30 min, washed with PBS solution, and prehybridized at 37°C for 30 min before hybridization. The prehybridized slides were then incubated with lncRNA-probe in hybridization solution at 37°C for 16 h. After hybridization, the slides were washed six times with prewarmed wash buffer and PBS solution. Finally, the slides were counterstained with DAPI and visualized using a confocal laser-scanning microscope (Zeiss 800, Germany).</p>
</sec>
<sec id="s4r">
<title>Quantitative Real-time RT-PCR</title>
<p>Total RNA was extracted by using Trizol reagent (Invitrogen, USA) according to manufacturer’s protocol. Total RNA (0.5μg) was reverse transcribed by using the TransScript reverse transcriptase (GMO technology, Beijing) to obtain cDNA. The RNA levels were determined using SYBR Green I incorporation method on ABI 7500 fast Real Time PCR system (Applied Biosystems, USA), the expression levels of mRNA were calculated by relative quantitative 2<sup>−△△CT</sup> method. The primers are: Mus lncDACH1 Forward: 5′-AAGATAGGATGTTGGGGCAG-3′ Mus lncDACH1 Reverse: 5′-ACCATAGCACAAACACTTCC-3′ Mus Dystrophin Forward: 5′- CGGGTTGGCTTTGAATGCTC -3′ Mus Dystrophin Reverse: 5′- AGTCTTTGGGTGGCTGAGTG -3′ Mus DACH1 Forward:5′-AACCGCAAGAGACAGCATCG-3′ Mus DACH1 Reverse: 5′-GGACAGGCCATCAGGAAACAG-3′ Mus SCN5a Forward: 5′- GAAGGAACGCAGCACAGACAG-3′ Mus SCN5a Reverse: 5′- CATCGCCCTTGACCCATACTA -3′ Mus Hadhb Forward: 5′- CCAAGAAGGCACAGGATGAAG -3′ Mus Hadhb Reverse: 5′- CCAGTGAGGAAGGACGGATG -3</p>
</sec>
<sec id="s4s">
<title>Western blot</title>
<p>The total, membrane and cytoplasmic protein samples were extracted from cardiac tissues of C57BL/6 mice for immunoblotting analysis. Total protein was collected with the treatment of RIPA lysis buffer (Beyotime, Beijing, China) and a protease inhibitor cocktail (Roche, Basel, Switzerland) at 4°C followed by centrifugation. Extraction of surface and cytoplasmic proteins was conducted using the Surface and Cytoplasmic Protein Reagent Kit (Cat#P0033; Beyotime, Shanghai, China) according to the manufacturer’s instructions. Protein samples were fractionated by SDS-PAGE and then transferred to PVDF membrane. The membranes were blocked in Tris-buffered saline containing 5% milk and then incubated with primary antibodies at 4°C overnight. The primary antibodies include anti-Nav1.5 (ASC005, Alomone, 1:200), anti-dystrophin (MANDYS8, SIGMA, 1:500). The anti- β-actin (1:20000 dilution, 66009-1-Ig, Proteintech) and anti-N-cadherin antibody (Cat#ab76011, 1:5000; Abcam, Cambridge, UK) were used as internal controls. Western blot bands were captured on the Odyssey Infrared Imaging System (LI-COR Biosciences, USA) and quantified with Odyssey v1.2 software by measuring the band intensity (area × OD) in each group. The band intensity was normalized to the internal control. All antibodies were diluted in PBS buffer.</p>
</sec>
<sec id="s4t">
<title>RNA pulldown and immunoblotting</title>
<p>The RNA pull-down was performed as described in the previous study<sup><xref ref-type="bibr" rid="c13">13</xref></sup>. Briefly, Biotin-labeled, full length lncDACH1 RNA and antisense RNA were prepared with the Biotin RNA Labeling Mix (Roche) and T7 RNA polymerase (Roche). Biotinylated RNAs were treated with RNase-free DNase I (Invitrogen) and purified on G-50 Sephadex Quick Spin columns (Roche). Biotinylated RNA (17μg) was heated to 65°C for 10 min and slowly cooled to 4°C. Then the RNA was mixed with tissue extracts in pulldown buffer supplemented with tRNA (0.1 μg/μl) and incubated at 4°C for 2 h. Washed Streptavidin agarose beads (60 μl, Invitrogen) were added to each binding reaction and further incubated at 4°C for 1 h. Beads were washed briefly five times in pulldown buffer and boiled in SDS buffer, and the retrieved protein was visualized by immunoblotting.</p>
</sec>
<sec id="s4u">
<title>RNA immunoprecipitation (RIP)</title>
<p>RNA immunoprecipitation (RIP) experiments were performed by using a Magna RIPTM RNA-Binding Protein Immunoprecipitation Kit (Millipore, USA) as previously reported<sup><xref ref-type="bibr" rid="c13">13</xref></sup>. Briefly, heart tissue was pieced and lysed in 220 μl of lysis buffer containing protease inhibitors and RNase Inhibitor and centrifuged at 14,000 × g for 10 min. The supernatants were incubated with anti-dystrophin, anti-hadhb and anti-rabbit IgG antibody for overnight at 4°C with gentle rotation. Protein G magnetic beads (50 μl) were added and incubated at RT with gentle rotation for 3 h. RNA was extracted with 400 μl phenol:chloroform:isoamyl alcohol (125:24:1, pH = 4.3) according to the manufacturer’s instructions before quantitation by RT-qPCR.</p>
</sec>
<sec id="s4v">
<title>Mouse models of heart failure (HF) by transaortic constriction (TAC) and by coronary artery ligation</title>
<p>Mice were randomly divided into sham and TAC groups. In each group, mice were anesthetized with 2,2,2-tribromoethanol (200 mg/kg, i.p.) for TAC model. The animal was orally intubated with 20-gauge tube, and ventilated (mouse ventilator, UGO BASILE, Biological Research Apparatus, Italy) at the respiratory rate of 100 breaths/min with a tidal volume of 0.3 ml. The transverse aorta was constricted by a 6-0 silk suture ligature tied firmly against a 27-gauge needle between the carotid arteries. Then, the needle was promptly removed to yield a constriction of 0.4 mm in diameter. For sham group mice, the animals received the same procedures without aorta constriction.</p>
</sec>
<sec id="s4w">
<title>Statistics</title>
<p>Data are expressed as mean ± SEM. Statistical analysis was performed using unpaired Student’s t test or One-Way Analysis of Variance (ANOVA) followed by Tukey’s post-hoc analysis. A <italic>P</italic>&lt; 0.05 was considered statistically different.v</p>
</sec>
</sec>
</body>
<back>
<ack>
<title>Acknowledgements</title>
<p>This work was supported by National Key R&amp;D Program of China (2017YFC1307404 to Z. P.), National Natural Science Foundation of China (82070344, 81870295 to Z. P. 81730012, 81861128022 to B. Y.), Heilongjiang Touyan Innovation Team Program and CAMS Innovation Fund for Medical Sciences (CIFMS, 2019-I2M-5-078 to B. Y.).</p>
</ack>
<sec id="s5">
<title>Declarations</title>
<sec id="s5a">
<title>Author contributions</title>
<p>Genlong Xue, YZ, JY, performed experiments, analyzed data, and prepared the manuscript. Ying Yang, RZ, DL, TT,XZ, CL, XL, JY, KS, YG, XL and GY helped perform experiments and collect data. BY and YJL oversaw the project and proofread the manuscript. ZP designed the project, oversaw the experiments and prepared the manuscript.</p>
</sec>
<sec id="s5b" sec-type="data-availability">
<title>Data availability</title>
<p>The data that support the findings of this study and unique materials are available from the corresponding authors upon reasonable request. Source data are provided with this paper. Additional data related to this paper may be requested from the authors.</p>
</sec>
</sec>
<ref-list>
<title>References</title>
<ref id="c1"><label>1.</label><mixed-citation publication-type="journal"><person-group><string-name><surname>Rook</surname> <given-names>MB</given-names></string-name>, <string-name><surname>Evers</surname> <given-names>MM</given-names></string-name>, <string-name><surname>Vos</surname> <given-names>MA</given-names></string-name>, <string-name><surname>Bierhuizen</surname> <given-names>MF</given-names></string-name></person-group>. <article-title>Biology of cardiac sodium channel Nav1.5 expression</article-title>. <source>Cardiovasc Res</source> <volume>93</volume>, <fpage>12</fpage>–<lpage>23</lpage> (<year>2012</year>).</mixed-citation></ref>
<ref id="c2"><label>2.</label><mixed-citation publication-type="journal"><person-group><string-name><surname>Marionneau</surname> <given-names>C</given-names></string-name>, <string-name><surname>Abriel</surname> <given-names>H</given-names></string-name></person-group>. <article-title>Regulation of the cardiac Na+ channel NaV1.5 by post-translational modifications</article-title>. <source>J Mol Cell Cardiol</source> <volume>82</volume>, <fpage>36</fpage>–<lpage>47</lpage> (<year>2015</year>).</mixed-citation></ref>
<ref id="c3"><label>3.</label><mixed-citation publication-type="journal"><person-group><string-name><surname>Ruan</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Liu</surname> <given-names>N</given-names></string-name>, <string-name><surname>Priori</surname> <given-names>SG</given-names></string-name></person-group>. <article-title>Sodium channel mutations and arrhythmias</article-title>. <source>Nat Rev Cardiol</source> <volume>6</volume>, <fpage>337</fpage>–<lpage>348</lpage> (<year>2009</year>).</mixed-citation></ref>
<ref id="c4"><label>4.</label><mixed-citation publication-type="journal"><person-group><string-name><surname>Abriel</surname> <given-names>H</given-names></string-name>, <string-name><surname>Rougier</surname> <given-names>JS</given-names></string-name>, <string-name><surname>Jalife</surname> <given-names>J</given-names></string-name></person-group>. <article-title>Ion channel macromolecular complexes in cardiomyocytes: roles in sudden cardiac death</article-title>. <source>Circ Res</source> <volume>116</volume>, <fpage>1971</fpage>–<lpage>1988</lpage> (<year>2015</year>).</mixed-citation></ref>
<ref id="c5"><label>5.</label><mixed-citation publication-type="journal"><person-group><string-name><surname>Lapidos</surname> <given-names>KA</given-names></string-name>, <string-name><surname>Kakkar</surname> <given-names>R</given-names></string-name>, <string-name><surname>McNally</surname> <given-names>EM</given-names></string-name></person-group>. <article-title>The dystrophin glycoprotein complex: signaling strength and integrity for the sarcolemma</article-title>. <source>Circ Res</source> <volume>94</volume>, <fpage>1023</fpage>–<lpage>1031</lpage> (<year>2004</year>).</mixed-citation></ref>
<ref id="c6"><label>6.</label><mixed-citation publication-type="journal"><person-group><string-name><surname>Gavillet</surname> <given-names>B</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Cardiac sodium channel Nav1.5 is regulated by a multiprotein complex composed of syntrophins and dystrophin</article-title>. <source>Circ Res</source> <volume>99</volume>, <fpage>407</fpage>–<lpage>414</lpage> (<year>2006</year>).</mixed-citation></ref>
<ref id="c7"><label>7.</label><mixed-citation publication-type="journal"><person-group><string-name><surname>Petitprez</surname> <given-names>S</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>SAP97 and dystrophin macromolecular complexes determine two pools of cardiac sodium channels Nav1.5 in cardiomyocytes</article-title>. <source>Circ Res</source> <volume>108</volume>, <fpage>294</fpage>–<lpage>304</lpage> (<year>2011</year>).</mixed-citation></ref>
<ref id="c8"><label>8.</label><mixed-citation publication-type="journal"><person-group><string-name><surname>Quinn</surname> <given-names>JJ</given-names></string-name>, <string-name><surname>Chang</surname> <given-names>HY</given-names></string-name></person-group>. <article-title>Unique features of long non-coding RNA biogenesis and function</article-title>. <source>Nat Rev Genet</source> <volume>17</volume>, <fpage>47</fpage>–<lpage>62</lpage> (<year>2016</year>).</mixed-citation></ref>
<ref id="c9"><label>9.</label><mixed-citation publication-type="journal"><person-group><string-name><surname>Bar</surname> <given-names>C</given-names></string-name>, <string-name><surname>Chatterjee</surname> <given-names>S</given-names></string-name>, <string-name><surname>Thum</surname> <given-names>T</given-names></string-name></person-group>. <article-title>Long Noncoding RNAs in Cardiovascular Pathology, Diagnosis, and Therapy</article-title>. <source>Circulation</source> <volume>134</volume>, <fpage>1484</fpage>–<lpage>1499</lpage> (<year>2016</year>).</mixed-citation></ref>
<ref id="c10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Long</surname> <given-names>QQ</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Long Noncoding RNA Kcna2 Antisense RNA Contributes to Ventricular Arrhythmias via Silencing Kcna2 in Rats With Congestive Heart Failure</article-title>. <source>J Am Heart Assoc</source> <volume>6</volume>, (<year>2017</year>).</mixed-citation></ref>
<ref id="c11"><label>11.</label><mixed-citation publication-type="journal"><person-group><string-name><surname>Zhu</surname> <given-names>P</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Long noncoding RNA MALAT1 downregulates cardiac transient outward potassium current by regulating miR-200c/HMGB1 pathway</article-title>. <source>J Cell Biochem</source> <volume>119</volume>, <fpage>10239</fpage>–<lpage>10249</lpage> (<year>2018</year>).</mixed-citation></ref>
<ref id="c12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhang</surname> <given-names>Y</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Long non-coding RNA CCRR controls cardiac conduction via regulating intercellular coupling</article-title>. <source>Nat Commun</source> <volume>9</volume>, <fpage>4176</fpage> (<year>2018</year>).</mixed-citation></ref>
<ref id="c13"><label>13.</label><mixed-citation publication-type="journal"><person-group><string-name><surname>Cai</surname> <given-names>B</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Long Noncoding RNA-DACH1 (Dachshund Homolog 1) Regulates Cardiac Function by Inhibiting SERCA2a (Sarcoplasmic Reticulum Calcium ATPase 2a)</article-title>. <source>Hypertension</source> <volume>74</volume>, <fpage>833</fpage>–<lpage>842</lpage> (<year>2019</year>).</mixed-citation></ref>
<ref id="c14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Cai</surname> <given-names>B</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Targeting LncDACH1 promotes cardiac repair and regeneration after myocardium infarction</article-title>. <source>Cell death and differentiation</source>, (<year>2020</year>).</mixed-citation></ref>
<ref id="c15"><label>15.</label><mixed-citation publication-type="journal"><person-group><string-name><surname>Baba</surname> <given-names>S</given-names></string-name>, <string-name><surname>Dun</surname> <given-names>W</given-names></string-name>, <string-name><surname>Cabo</surname> <given-names>C</given-names></string-name>, <string-name><surname>Boyden</surname> <given-names>PA</given-names></string-name></person-group>. <article-title>Remodeling in cells from different regions of the reentrant circuit during ventricular tachycardia</article-title>. <source>Circulation</source> <volume>112</volume>, <fpage>2386</fpage>–<lpage>2396</lpage> (<year>2005</year>).</mixed-citation></ref>
<ref id="c16"><label>16.</label><mixed-citation publication-type="journal"><person-group><string-name><surname>Valdivia</surname> <given-names>CR</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Increased late sodium current in myocytes from a canine heart failure model and from failing human heart</article-title>. <source>J Mol Cell Cardiol</source> <volume>38</volume>, <fpage>475</fpage>–<lpage>483</lpage> (<year>2005</year>).</mixed-citation></ref>
<ref id="c17"><label>17.</label><mixed-citation publication-type="journal"><person-group><string-name><surname>Xi</surname> <given-names>Y</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Increased late sodium currents are related to transcription of neuronal isoforms in a pressure-overload model</article-title>. <source>Eur J Heart Fail</source> <volume>11</volume>, <fpage>749</fpage>–<lpage>757</lpage> (<year>2009</year>).</mixed-citation></ref>
<ref id="c18"><label>18.</label><mixed-citation publication-type="journal"><person-group><string-name><surname>Dybkova</surname> <given-names>N</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Differential regulation of sodium channels as a novel proarrhythmic mechanism in the human failing heart</article-title>. <source>Cardiovasc Res</source> <volume>114</volume>, <fpage>1728</fpage>–<lpage>1737</lpage> (<year>2018</year>).</mixed-citation></ref>
<ref id="c19"><label>19.</label><mixed-citation publication-type="journal"><person-group><string-name><surname>Yao</surname> <given-names>RW</given-names></string-name>, <string-name><surname>Wang</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Chen</surname> <given-names>LL</given-names></string-name></person-group>. <article-title>Cellular functions of long noncoding RNAs</article-title>. <source>Nat Cell Biol</source> <volume>21</volume>, <fpage>542</fpage>–<lpage>551</lpage> (<year>2019</year>).</mixed-citation></ref>
<ref id="c20"><label>20.</label><mixed-citation publication-type="journal"><person-group><string-name><surname>Ulitsky</surname> <given-names>I</given-names></string-name>, <string-name><surname>Bartel</surname> <given-names>DP</given-names></string-name></person-group>. <article-title>lincRNAs: genomics, evolution, and mechanisms</article-title>. <source>Cell</source> <volume>154</volume>, <fpage>26</fpage>–<lpage>46</lpage> (<year>2013</year>).</mixed-citation></ref>
<ref id="c21"><label>21.</label><mixed-citation publication-type="journal"><person-group><string-name><surname>Shy</surname> <given-names>D</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>PDZ domain-binding motif regulates cardiomyocyte compartment-specific NaV1.5 channel expression and function</article-title>. <source>Circulation</source> <volume>130</volume>, <fpage>147</fpage>–<lpage>160</lpage> (<year>2014</year>).</mixed-citation></ref>
<ref id="c22"><label>22.</label><mixed-citation publication-type="journal"><person-group><string-name><surname>Tang</surname> <given-names>B</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>UBC9 regulates cardiac sodium channel Nav1.5 ubiquitination, degradation and sodium current density</article-title>. <source>J Mol Cell Cardiol</source> <volume>129</volume>, <fpage>79</fpage>–<lpage>91</lpage> (<year>2019</year>).</mixed-citation></ref>
<ref id="c23"><label>23.</label><mixed-citation publication-type="journal"><person-group><string-name><surname>van Bemmelen</surname> <given-names>MX</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Cardiac voltage-gated sodium channel Nav1.5 is regulated by Nedd4-2 mediated ubiquitination</article-title>. <source>Circ Res</source> <volume>95</volume>, <fpage>284</fpage>–<lpage>291</lpage> (<year>2004</year>).</mixed-citation></ref>
<ref id="c24"><label>24.</label><mixed-citation publication-type="journal"><person-group><string-name><surname>Hu</surname> <given-names>Y</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Ubiquitination-activating enzymes UBE1 and UBA6 regulate ubiquitination and expression of cardiac sodium channel Nav1.5</article-title>. <source>Biochem J</source> <volume>477</volume>, <fpage>1683</fpage>–<lpage>1700</lpage> (<year>2020</year>).</mixed-citation></ref>
<ref id="c25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Turan</surname> <given-names>NN</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>The endosomal trafficking regulator LITAF controls the cardiac Nav1.5 channel via the ubiquitin ligase NEDD4-2</article-title>. <source>J Biol Chem</source>, (<year>2020</year>).</mixed-citation></ref>
<ref id="c26"><label>26.</label><mixed-citation publication-type="journal"><person-group><string-name><surname>Han</surname> <given-names>D</given-names></string-name>, <string-name><surname>Tan</surname> <given-names>H</given-names></string-name>, <string-name><surname>Sun</surname> <given-names>C</given-names></string-name>, <string-name><surname>Li</surname> <given-names>G</given-names></string-name></person-group>. <article-title>Dysfunctional Nav1.5 channels due to SCN5A mutations</article-title>. <source>Exp Biol Med (Maywood)</source> <volume>243</volume>, <fpage>852</fpage>–<lpage>863</lpage> (<year>2018</year>).</mixed-citation></ref>
<ref id="c27"><label>27.</label><mixed-citation publication-type="journal"><person-group><string-name><surname>Savio-Galimberti</surname> <given-names>E</given-names></string-name>, <string-name><surname>Argenziano</surname> <given-names>M</given-names></string-name>, <string-name><surname>Antzelevitch</surname> <given-names>C</given-names></string-name></person-group>. <article-title>Cardiac Arrhythmias Related to Sodium Channel Dysfunction</article-title>. <source>Handb Exp Pharmacol</source> <volume>246</volume>, <fpage>331</fpage>–<lpage>354</lpage> (<year>2018</year>).</mixed-citation></ref>
<ref id="c28"><label>28.</label><mixed-citation publication-type="journal"><person-group><string-name><surname>Johnsson</surname> <given-names>P</given-names></string-name>, <string-name><surname>Lipovich</surname> <given-names>L</given-names></string-name>, <string-name><surname>Grander</surname> <given-names>D</given-names></string-name>, <string-name><surname>Morris</surname> <given-names>KV</given-names></string-name></person-group>. <article-title>Evolutionary conservation of long non-coding RNAs; sequence, structure, function</article-title>. <source>Biochim Biophys Acta</source> <volume>1840</volume>, <fpage>1063</fpage>–<lpage>1071</lpage> (<year>2014</year>).</mixed-citation></ref>
<ref id="c29"><label>29.</label><mixed-citation publication-type="journal"><person-group><string-name><surname>Tsagakis</surname> <given-names>I</given-names></string-name>, <string-name><surname>Douka</surname> <given-names>K</given-names></string-name>, <string-name><surname>Birds</surname> <given-names>I</given-names></string-name>, <string-name><surname>Aspden</surname> <given-names>JL</given-names></string-name></person-group>. <article-title>Long non-coding RNAs in development and disease: conservation to mechanisms</article-title>. <source>J Pathol</source> <volume>250</volume>, <fpage>480</fpage>–<lpage>495</lpage> (<year>2020</year>).</mixed-citation></ref>
<ref id="c30"><label>30.</label><mixed-citation publication-type="journal"><person-group><string-name><surname>Maeder</surname> <given-names>ML</given-names></string-name>, <string-name><surname>Linder</surname> <given-names>SJ</given-names></string-name>, <string-name><surname>Cascio</surname> <given-names>VM</given-names></string-name>, <string-name><surname>Fu</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Ho</surname> <given-names>QH</given-names></string-name>, <string-name><surname>Joung</surname> <given-names>JK</given-names></string-name></person-group>. <article-title>CRISPR RNA-guided activation of endogenous human genes</article-title>. <source>Nat Methods</source> <volume>10</volume>, <fpage>977</fpage>–<lpage>979</lpage> (<year>2013</year>).</mixed-citation></ref>
</ref-list>
<sec id="d1e2094">
<title>Supplementary Files</title>
<fig id="data1">
<label>Supplemental Figure 1.</label>
    <caption><title>The conserved fragment of lncDACH1(cF-lncDACH1) inhibited sodium channel function in mice.</title><p><bold>(A)</bold> The mRNA levels of SCN5A and dystrophin. N=4-5. <bold>(B)</bold> Kinetics of <italic>I</italic><sub>Na</sub>. N=6-17 cells from 3 or more mice.</p></caption>
<graphic mime-subtype="jpg" xlink:href="156367-data1.jpg" mimetype="image"/>
</fig>
    <fig id="data2">
<label>Supplemental Figure 2.</label>
        <caption><title>Effects of cF-lncDACH1 overexpression on sodium channel expression and function in cultured neonatal cardiomyocytes.</title><p>(A) Verification of the expression of cF-lncDACH1 after transfection of adenovirus carrying cF-lncDACH1. N=8 from 3 independent cultures. *P&lt;0.05 versus NC (negative control, empty plasmid). P-values were determined by unpaired t test. <bold>(B)</bold> Peak <italic>I</italic><sub>Na</sub> currents, I-V curves and kinetics of <italic>I</italic><sub>Na</sub>. N=8-15 cells from 3 independent cultures. <bold>(C)</bold> Distribution of Nav1.5 and dystrophin by immunofluorescent staining. <bold>(D)</bold> The mRNA levels of dystrophin and SCN5A. N=8-12 from 3 independent cultures.</p></caption>
        <graphic mime-subtype="jpg" xlink:href="156367-data2.jpg" mimetype="image"/>
</fig>
    <fig id="data3">
<label>Supplemental Figure 3.</label>
        <caption><title>Schematic model for the construction of AAV9 virus carrying the dCas9-SAM system (A) to activate the transcription of dystrophin and tail-vein injection to mice (B).</title><p>VP64, VP64 transactivator; dCas9, deactivated CRISPR associated protein 9 nuclease. TSS, transcriptional start point.</p></caption>
        <graphic mime-subtype="jpg" xlink:href="156367-data3.jpg" mimetype="image"/>
</fig>
</sec>
</back>
<sub-article id="sa0" article-type="editor-report">
<front-stub>
<article-id pub-id-type="doi">10.7554/eLife.89690.1.sa3</article-id>
<title-group>
<article-title>eLife Assessment</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Colecraft</surname>
<given-names>Henry M</given-names>
</name>
<role specific-use="editor">Reviewing Editor</role>
<aff>
<institution-wrap>
<institution>Columbia University</institution>
</institution-wrap>
<city>New York</city>
<country>United States of America</country>
</aff>
</contrib>
</contrib-group>
<kwd-group kwd-group-type="evidence-strength">
<kwd>Convincing</kwd>
<kwd>Incomplete</kwd>
</kwd-group>
<kwd-group kwd-group-type="claim-importance">
<kwd>Valuable</kwd>
</kwd-group>
</front-stub>
<body>
<p>This study presents a <bold>valuable</bold> contribution to cardiac arrhythmia research by demonstrating long noncoding RNA Dachshund homolog 1 (lncDACH1) tunes sodium channel functional expression and affects cardiac action potential conduction and rhythms. Whereas the evidence for functional impact of lncDACH1 expression on cardiac sodium currents and rhythms is <bold>convincing</bold>, biochemical experiments addressing the mechanism of changes in sodium channel expression and subcellular localization are <bold>incomplete</bold>.</p>
</body>
</sub-article>
<sub-article id="sa1" article-type="referee-report">
<front-stub>
<article-id pub-id-type="doi">10.7554/eLife.89690.1.sa2</article-id>
<title-group>
<article-title>Reviewer #1 (Public Review):</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<anonymous/>
<role specific-use="referee">Reviewer</role>
</contrib>
</contrib-group>
</front-stub>
<body>
<p>Summary:</p>
<p>In this study, the authors show that a long-non coding RNA lncDACH1 inhibits sodium currents in cardiomyocytes by binding to and altering the localization of dystrophin. The authors use a number of methodologies to demonstrate that lncDACH1 binds to dystrophin and disrupts its localization to the membrane, which in turn downregulates NaV1.5 currents. Knockdown of lncDACH1 upregulates NaV1.5 currents. Furthermore, in heart failure, lncDACH1 is shown to be upregulated which suggests that this mechanism may have pathophysiolgoical relevance.</p>
<p>Strengths:</p>
<p>1. This study presents a novel mechanism of Na channel regulation which may be pathophysiologically important.</p>
<p>2. The experiments are comprehensive and systematically evaluate the physiological importance of lncDACH1.</p>
<p>Weaknesses:</p>
<p>1. What is indicated by the cytoplasmic level of NaV1.5, a transmembrane protein? The methods do not provide details regarding how this was determined. Do you authors means NaV1.5 retained in various intracellular organelles?</p>
<p>2. What is the negative control in Fig. 2b, Fig. 4b, Fig. 6e, Fig. 7c? The maximum current amplitude in these seem quite different. -40 pA/pF in some, -30 pA/pF in others and this value seems to be different than in CMs from WT mice (&lt;-20 pA/pF). Is there an explanation for what causes this variability between experiments and/or increase with transfection of the negative control? This is important since the effect of lncDACH1 is less than 50% reduction and these could fall in the range depending on the amplitude of the negative control.</p>
<p>3. NaV1.5 staining in Fig. 1E is difficult to visualize and to separate from lncDACH1. Is it possible to pseudocolor differently so that all three channels can be visualized/distinguished more robustly?</p>
<p>4. The authors use shRNA to knockdown lncDACH1 levels. It would be helpful to have a scrambled ShRNA control.</p>
<p>5. Is there any measurement on the baseline levels of LncDACH1 in wild-type mice? It seems quite low and yet is a substantial increase in NaV1.5 currents upon knocking down LncDACH1. By comparison, the level of LncDACH1 seems to be massively upregulated in TAC models. Have the authors measured NaV1.5 currents in these cells? Furthermore, does LncDACH1 knockdown evoke a larger increase in NaV1.5 currents?</p>
<p>6. What do error bars denote in all bar graphs, and also in the current voltage relationships?</p>
</body>
</sub-article>
<sub-article id="sa2" article-type="referee-report">
<front-stub>
<article-id pub-id-type="doi">10.7554/eLife.89690.1.sa1</article-id>
<title-group>
<article-title>Reviewer #2 (Public Review):</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<anonymous/>
<role specific-use="referee">Reviewer</role>
</contrib>
</contrib-group>
</front-stub>
<body>
<p>This manuscript by Xue et al. describes the effects of a long noncoding RNA, lncDACH1, on the localization of Nav channel expression, the magnitude of INa, and arrhythmia susceptibility in the mouse heart. Because lncDACH1 was previously reported to bind and disrupt membrane expression of dystrophin, which in turn is required for proper Nav1.5 localization, much of the findings are inferred through the lens of dystrophin alterations.</p>
<p>The results report that cardiomyocyte-specific transgenic overexpression of lncDACH1 reduces INa in isolated cardiomyocytes; measurements in whole heart show a corresponding reduction in conduction velocity and enhanced susceptibility to arrhythmia. The effect on INa was confirmed in isolated WT mouse cardiomyocytes infected with a lncDACH1 adenoviral construct. Importantly, reducing lncDACH1 expression via either a cardiomyocyte-specific knockout or using shRNA had the opposite effect: INa was increased in isolated cells, as was conduction velocity in heart. Experiments were also conducted with a fragment of lnDACH1 identified by its conservation with other mammalian species. Overexpression of this fragment resulted in reduced INa and greater proarrhythmic behavior. Alteration of expression was confirmed by qPCR.</p>
<p>The mechanism by which lnDACH1 exerts its effects on INa was explored by measuring protein levels from cell fractions and immunofluorescence localization in cells. In general, overexpression was reported to reduce Nav1.5 and dystrophin levels and knockout or knockdown increased them.</p>
</body>
</sub-article>
<sub-article id="sa3" article-type="referee-report">
<front-stub>
<article-id pub-id-type="doi">10.7554/eLife.89690.1.sa0</article-id>
<title-group>
<article-title>Reviewer #3 (Public Review):</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<anonymous/>
<role specific-use="referee">Reviewer</role>
</contrib>
</contrib-group>
</front-stub>
<body>
<p>Summary:</p>
<p>In this manuscript, the authors report the first evidence of Nav1.5 regulation by a long noncoding RNA, LncRNA-DACH1, and suggest its implication in the reduction in sodium current observed in heart failure. Since no direct interaction is observed between Nav1.5 and the LncRNA, they propose that the regulation is via dystrophin and targeting of Nav1.5 to the plasma membrane.</p>
<p>Strengths:</p>
<p>1. First evidence of Nav1.5 regulation by a long noncoding RNA.</p>
<p>
2. Implication of LncRNA-DACH1 in heart failure and mechanisms of arrhythmias.</p>
<p>
3. Demonstration of LncRNA-DACH1 binding to dystrophin.</p>
<p>
4. Potential rescuing of dystrophin and Nav1.5 strategy.</p>
<p>Weaknesses:</p>
<p>1. Main concern is that the authors do not provide evidence of how LncRNA-DACH1 regulates Nav1.5 protein level. The decrease in total Nav1.5 protein by about 50% seems to be the main consequence of the LncRNA on Nav1.5, but no mechanistic information is provided as to how this occurs.</p>
<p>
2. The fact that the total Nav1.5 protein is reduced by 50% which is similar to the reduction in the membrane reduction questions the main conclusion of the authors implicating dystrophin in the reduced Nav1.5 targeting. The reduction in membrane Nav1.5 could simply be due to the reduction in total protein.</p>
</body>
</sub-article>
</article>